NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球生物醫藥品市場

Global Biopharmaceuticals Market - 2019-2026

出版商 DataM Intelligence 商品編碼 739290
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
全球生物醫藥品市場 Global Biopharmaceuticals Market - 2019-2026
出版日期: 按訂單生產內容資訊: 英文
簡介

本報告提供全球生物醫藥品市場相關調查分析,提供產業分析,市場分析,各地區分析,競爭情形,主要企業等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 市場趨勢

  • 主要的發展
  • 未來市場預測

第5章 生物醫藥品市場:產業分析

  • 推動市場要素
  • 阻礙市場要素
  • 威脅和機會
  • 波特的五力分析

第6章 生物醫藥品市場:市場分析

  • 生物醫藥品市場:各產品
  • 生物醫藥品市場:各用途

第7章 生物醫藥品市場:各地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 中東·非洲
  • 南美

第8章 生物醫藥品市場:競爭情形

  • 市場佔有率分析
  • M&A分析
  • 新產品的銷售

第9章 生物醫藥品市場:企業簡介

  • Abbvie Inc.
  • Amgen
  • Bayer
  • Biogen
  • Bristol-Myers Squibb
  • ELI Lilly and Company
  • Johnson and Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk
  • Pfizer
  • Glaxosmithkline PLC
  • Sanofi S.A
  • 武田藥品工業
目錄

The global Biopharmaceuticals market was valued at USD xx million in 2016, USD xx million in 2017, and is estimated to reach USD xx million by 2025, with a CAGR of xx% during the forecast period (2018-2025).

Biopharmaceuticals are medicinal drugs which helps in prevention and treatment of various diseases such as cardiovascular disease, rheumatoid arthritis, psoriatic arthritis, psoriasis, anemia arising from chemotherapy, chronic renal failure, cancer, and diabetes.

The market is driven by several factors such as ability of biopharmaceuticals to treat previously untreatable diseases, increased uptake of biopharmaceuticals, huge market demand, and growing aging population. But the market is affected by the challenging development process, and stringent regulatory framework.

Product Insights:

The global Biopharmaceuticals market is segmented by product type such as Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Synthetic Immunomodulators, Vaccines & Recombinant Enzymes, and Others. Among these, Monoclonal antibodies are the fastest growing segment. Some of the top-selling monoclonal antibodies include Adalimumab, Infliximab, Rituximab and Bevacizumab.

Application Insights:

Based on applications, the global biopharmaceuticals market can be segmented into oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, hormonal disorders, disease prevention, cardiovascular diseases, neurological diseases and other diseases. Oncology is the largest segment in the biopharmaceuticals market as biopharmaceuticals have wide applications in the pharmaceutical industry.

Regional Insights:

Geographically, the market is segmented into North America, South America, Europe, Asia Pacific and RoW. North America is the largest market for biopharmaceuticals due to technological advancements in the region. The North America market for biopharmaceuticals was valued at US$ 64.7 Bn in 2014 and is expected to reach grow at a CAGR of 9.5% over the forecast period.

The graph represents the worldwide biopharmaceutical-related venture capital investments in 2010. In that year, the venture capital investments in this sector amounted to 8.23 billion U.S. dollars in the United States. The worldwide venture capital investments amounted to 12.48 billion U.S. dollars.

Competitive Insights:

The major companies in the Biopharmaceuticals market includes Abbvie Inc., Amgen, Bayer, Biogen, Bristol-Myers Squibb, ELI Lilly and Company, Johnson and Johnson, Merck & Co. Inc., Novartis AG, Novo Nordisk, Pfizer, Glaxosmithkline PLC, Sanofi S.A, and Takeda Pharmaceutical.

Recent Development in Biopharmaceuticals market:

In Sept 2017, Arizona-based company HSRx Biopharmaceutical announced that its orally administered broad-spectrum antiviral drug HSRx 431™ is effective against the Zika virus. They plan to test their claim by conducting human trials in 2017, and if these are found to be successful, they plan to seek accelerated drug approval from the U.S. FDA.

Challenges:

There are several challenges faced in pharmaceuticals market. One of the challenge is the requirement of cold storage for almost all the biopharmaceuticals. This limits their reach in the developing and third world countries. The process of developing a biopharmaceutical is also extremely difficult, as it involves living biological systems which limits the scalability, as scaling a biological system is different from scaling an equipment-based system.

The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.

Why purchase the report?

  • Visualize the composition of the Biopharmaceuticals in market across each indication, in terms of type and applications, highlighting the key commercial assets and players.
  • Identify commercial opportunities in Biopharmaceuticals by analyzing trends and co-development deals.
  • This is the most comprehensive study on Biopharmaceuticals to date.
  • Excel data sheet with thousands of data points of the Biopharmaceuticals market - level 4/5 segmentation
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
  • Product mapping in excel for the key Biopharmaceuticals products of all major market players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Research methodology
  • 1.2 Scope of the Report

Chapter 2 Global Biopharmaceuticals Market -Trends

  • 2.1 Key Trends & Developments

Chapter 3 Global Biopharmaceuticals Market - Industry Analysis

  • 3.1 Industry Impact Factors (Drivers & Restraints)
  • 3.2 Competitive Intensity- Porter 5 Forces
  • 3.3 Regulatory Analysis
  • 3.4 Production Analysis

Chapter 4 Global Biopharmaceuticals Market- Product Analysis

  • 4.1. Biopharmaceuticals Market - By Type
    • 4.1.1. Monoclonal Antibodies
      • 4.1.1.1. Anti-Cancer Monoclonal Antibodies
      • 4.1.1.2. Anti-Inflammatory Monoclonal Antibodies
      • 4.1.1.3. Other Monoclonal Antibodies
    • 4.1.2. Recombinant Growth Factors
      • 4.1.2.1. Erythropoietin
      • 4.1.2.2. Granulocyte Colony Stimulating Factor
    • 4.1.3. Purified Proteins
      • 4.1.3.1. Leukemia Inhibitory Factor (LIF)
      • 4.1.3.2. P53 Protein
      • 4.1.3.3. P38 Protein
    • 4.1.4. Recombinant Proteins
      • 4.1.4.1. Serum Albumin
      • 4.1.4.2. Amyloid Protein
      • 4.1.4.3. Defensin
      • 4.1.4.4. Cyclase
      • 4.1.4.5. Caspase
      • 4.1.4.6. Cathepsin
    • 4.1.5. Recombinant Hormones
      • 4.1.5.1. Recombinant Human Growth Hormone (HGH)
      • 4.1.5.2. Recombinant Insulin
    • 4.1.6. Synthetic Immnunomodulators
      • 4.1.6.1. Cytokines, Interferones, Interleukins
      • 4.1.6.2. Tumour Necrosis Factor (TNF)
    • 4.1.7. Vaccines
      • 4.1.7.1. Recombinant Vaccines
      • 4.1.7.2. Conventional Vaccines
    • 4.1.8. Recombinant Enzymes
      • 4.1.8.1. Enterokinase
      • 4.1.8.2. Transferrin
    • 4.1.9. Others
      • 4.1.9.1. Blood Factors
      • 4.1.9.2. Others
  • 4.2. Biopharmaceuticals Market - By Applications
    • 4.2.1. Oncology
    • 4.2.2. Inflammatory and Infectious Diseases
    • 4.2.3. Autoimmune Disorders
    • 4.2.4. Metabolic Disorders
    • 4.2.5. Hormonal Disorders
    • 4.2.6. Disease Prevention

\4.2.7. Cardiovascular Diseases

    • 4.2.8. Neurological Diseases
    • 4.2.9. Others

Chapter 5 Global Biopharmaceuticals Market- Geographical Analysis

  • 5.1 North America
    • 5.1.1 The USA
    • 5.1.2 Canada
    • 5.1.3 Mexico
  • 5.2 Europe
    • 5.2.1 Germany
    • 5.2.2 France
    • 5.2.3 The UK
    • 5.2.4 Italy
    • 5.2.5 Spain
    • 5.2.7 Rest of Europe
  • 5.3 Asia Pacific
    • 5.3.1 China
    • 5.3.2 Japan
    • 5.3.3 India
    • 5.3.4 Australia
    • 5.3.5 Rest of Asia Pacific
  • 5.4 South America
    • 5.4.1 Brazil
    • 5.4.2 Argentina
    • 5.4.3 Rest of South America
  • 5.5 RoW

Chapter 6 Global Biopharmaceuticals Market - Competitive Landscape

  • 6.1 Market Share Analysis
  • 6.2 Merger and Acquisition Analysis
  • 6.3 New Product Launches

Chapter 7 Global Biopharmaceuticals Market- Company Profiles

  • 7.1. Abbvie Inc.
  • 7.2. Amgen
  • 7.3. Bayer
  • 7.4. Biogen
  • 7.5. Bristol-Myers Squibb
  • 7.6. ELI Lilly and Company
  • 7.7. Johnson and Johnson
  • 7.8. Merck & Co., Inc.
  • 7.9. Novartis AG
  • 7.10. Novo Nordisk
  • 7.11. Pfizer
  • 7.12. Glaxosmithkline PLC
  • 7.13. Sanofi S.A
  • 7.14. Takeda Pharmaceutical